# Presurance Holdings, Inc.: financial statements, quarterly

PRHI · Nasdaq · CIK 1502292 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prhi.md) · [Financials](/companies/prhi/financials.md) · [Filings](/companies/prhi/filings.md) · [Insiders](/companies/prhi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prhi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [25.4](/filings/0000950170-24-126271.md) | [16.4 d](/filings/0000950170-25-046719.md) | [18.6](/filings/0000950170-25-071392.md) | [17.9](/filings/0001193125-25-179796.md) | [16.0](/filings/0001193125-25-277589.md) | [14.7 d](/filings/0001193125-26-129019.md) | [15.9](/filings/0001193125-26-221549.md) | [16.1](/filings/0001193125-26-346778.md) | [6.7](/filings/0001193125-25-277589.md) | [4.6 d](/filings/0001193125-26-129019.md) | [11.5](/filings/0001193125-26-221549.md) | [9.1](/filings/0001193125-26-346778.md) |
| Operating income | $m | [(5.3)](/filings/0000950170-24-126271.md) | [(19.9) d](/filings/0000950170-25-046719.md) | [0.5](/filings/0000950170-25-071392.md) | [(4.4)](/filings/0001193125-25-179796.md) | [(7.3)](/filings/0001193125-25-277589.md) | [(26.3) d](/filings/0001193125-26-129019.md) | [(4.4)](/filings/0001193125-26-221549.md) | [(2.0)](/filings/0001193125-26-346778.md) | [(2.9)](/filings/0001193125-25-277589.md) | [(14.9) d](/filings/0001193125-26-129019.md) | [(1.1)](/filings/0001193125-26-221549.md) | [2.1](/filings/0001193125-26-346778.md) |
| Interest expense | $m | [0.9](/filings/0000950170-24-126271.md) | [0.8 d](/filings/0000950170-25-046719.md) | [0.9](/filings/0000950170-25-071392.md) | [0.9](/filings/0001193125-25-179796.md) | [2.3](/filings/0001193125-25-277589.md) | [0.9 d](/filings/0001193125-26-129019.md) | [0.5](/filings/0001193125-26-221549.md) | [0.9](/filings/0001193125-26-346778.md) | [0.9](/filings/0001193125-25-277589.md) | [0.9 d](/filings/0001193125-26-129019.md) | [2.0](/filings/0001193125-26-221549.md) | [0.7](/filings/0001193125-26-346778.md) |
| Income tax | $m | [(0.5)](/filings/0000950170-24-126271.md) | [0.1 d](/filings/0000950170-25-046719.md) | [(0.2)](/filings/0000950170-25-071392.md) | [(0.3)](/filings/0001193125-25-179796.md) | [(1.4)](/filings/0001193125-25-277589.md) | [0.0 d](/filings/0001193125-26-129019.md) | [0.0](/filings/0001193125-26-221549.md) | [0.0](/filings/0001193125-26-346778.md) | [0.0](/filings/0001193125-25-277589.md) | [0.1 d](/filings/0001193125-26-129019.md) | [(0.0)](/filings/0001193125-26-221549.md) | [0.0](/filings/0001193125-26-346778.md) |
| Net income | $m | [(2.7)](/filings/0000950170-24-126271.md) | [(19.5) d](/filings/0000950170-24-039426.md) | [0.1](/filings/0000950170-24-059481.md) | [(4.0)](/filings/0000950170-24-096287.md) | [52.8](/filings/0000950170-24-126271.md) | [(24.6) d](/filings/0001193125-26-129019.md) | [0.5](/filings/0001193125-26-221549.md) | [2.1](/filings/0001193125-26-346778.md) | [(4.0)](/filings/0001193125-25-277589.md) | [(17.0) d](/filings/0001193125-26-129019.md) | [2.6](/filings/0001193125-26-221549.md) | [2.5](/filings/0001193125-26-346778.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0000950170-24-126271.md) | not reported | [0.01](/filings/0000950170-25-071392.md) | [(0.32)](/filings/0001193125-25-179796.md) | [4.32](/filings/0001193125-25-277589.md) | not reported | [0.04](/filings/0001193125-26-221549.md) | [1.17](/filings/0001193125-26-346778.md) | [(0.32)](/filings/0001193125-25-277589.md) | not reported | [0.15](/filings/0001193125-26-221549.md) | [0.68](/filings/0001193125-26-346778.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0000950170-24-126271.md) | not reported | [0.01](/filings/0000950170-25-071392.md) | [(0.32)](/filings/0001193125-25-179796.md) | [4.32](/filings/0001193125-25-277589.md) | not reported | [0.04](/filings/0001193125-26-221549.md) | [1.17](/filings/0001193125-26-346778.md) | [(0.32)](/filings/0001193125-25-277589.md) | not reported | [0.15](/filings/0001193125-26-221549.md) | [0.68](/filings/0001193125-26-346778.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [14.4](/filings/0000950170-23-062287.md) | [10.7](/filings/0000950170-25-046719.md) | [17.3](/filings/0000950170-24-059481.md) | [9.7](/filings/0000950170-24-096287.md) | [32.4](/filings/0000950170-24-126271.md) | [27.7](/filings/0001193125-26-129019.md) | [10.3](/filings/0000950170-25-071392.md) | [22.0](/filings/0001193125-25-179796.md) | [7.4](/filings/0001193125-25-277589.md) | [27.4](/filings/0001193125-26-346778.md) | [25.5](/filings/0001193125-26-221549.md) | [12.8](/filings/0001193125-26-346778.md) |
| Total assets | $m | [293](/filings/0000950170-23-062287.md) | [316](/filings/0000950170-25-046719.md) | [301](/filings/0000950170-24-059481.md) | [293](/filings/0000950170-24-096287.md) | [300](/filings/0000950170-24-126271.md) | [282](/filings/0001193125-26-129019.md) | [277](/filings/0000950170-25-071392.md) | [283](/filings/0001193125-25-179796.md) | [285](/filings/0001193125-25-277589.md) | [239](/filings/0001193125-26-346778.md) | [237](/filings/0001193125-26-221549.md) | [222](/filings/0001193125-26-346778.md) |
| Total liabilities | $m | [282](/filings/0000950170-23-062287.md) | [313](/filings/0000950170-25-046719.md) | [299](/filings/0000950170-24-059481.md) | [294](/filings/0000950170-24-096287.md) | [251](/filings/0000950170-24-126271.md) | [260](/filings/0001193125-26-129019.md) | [251](/filings/0000950170-25-071392.md) | [255](/filings/0001193125-25-179796.md) | [260](/filings/0001193125-25-277589.md) | [230](/filings/0001193125-26-346778.md) | [211](/filings/0001193125-26-221549.md) | [195](/filings/0001193125-26-346778.md) |
| Long-term debt | $m | [25.3](/filings/0000950170-23-062287.md) | [25.1](/filings/0000950170-25-046719.md) | [24.9](/filings/0000950170-24-059481.md) | [24.8](/filings/0000950170-24-096287.md) | [16.5](/filings/0000950170-24-126271.md) | [11.9](/filings/0001193125-26-129019.md) | [12.0](/filings/0000950170-25-071392.md) | [12.1](/filings/0001193125-25-179796.md) | [12.1](/filings/0001193125-25-277589.md) | [12.2](/filings/0001193125-26-346778.md) | [12.3](/filings/0001193125-26-221549.md) | [12.3](/filings/0001193125-26-346778.md) |
| Shareholders' equity | $m | [11.8](/filings/0000950170-23-062287.md) | [2.9](/filings/0000950170-25-046719.md) | [2.6](/filings/0000950170-24-059481.md) | [(1.2)](/filings/0000950170-24-096287.md) | [49.1](/filings/0000950170-24-126271.md) | [21.5](/filings/0001193125-26-129019.md) | [25.6](/filings/0000950170-25-071392.md) | [28.2](/filings/0001193125-25-179796.md) | [25.3](/filings/0001193125-25-277589.md) | [9.0](/filings/0001193125-26-346778.md) | [25.2](/filings/0001193125-26-221549.md) | [27.7](/filings/0001193125-26-346778.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.7 d](/filings/0000950170-23-062287.md) | [(12.7) d](/filings/0000950170-24-039426.md) | [8.2](/filings/0000950170-24-059481.md) | [(10.1) d](/filings/0000950170-24-096287.md) | [(10.7) d](/filings/0001193125-25-277589.md) | [(20.0) d](/filings/0001193125-26-129019.md) | [(15.3)](/filings/0001193125-26-221549.md) | [(2.8) d](/filings/0001193125-26-346778.md) | [(0.7) d](/filings/0001193125-25-277589.md) | [(25.2) d](/filings/0001193125-26-129019.md) | [(8.3)](/filings/0001193125-26-221549.md) | [(11.9) d](/filings/0001193125-26-346778.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | [0.2](/filings/0000950170-24-059481.md) | [0.2 d](/filings/0000950170-24-096287.md) | [0.5 d](/filings/0000950170-24-126271.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.1](/filings/0000950170-23-062287.md) | [12.2](/filings/0000950170-24-059481.md) | [12.2](/filings/0000950170-24-096287.md) | [12.2](/filings/0000950170-24-126271.md) | [12.2](/filings/0000950170-25-071392.md) | [12.2](/filings/0001193125-25-179796.md) | [12.2](/filings/0001193125-25-277589.md) | [12.2](/filings/0001193125-26-221549.md) | [1.7](/filings/0001193125-26-346778.md) | [12.2](/filings/0001193125-25-277589.md) | [17.2](/filings/0001193125-26-221549.md) | [3.7](/filings/0001193125-26-346778.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,746,092 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346778.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.